Abd El-Kaream Samir Ali, Hassan Nasser Ali Mohamed, Saleh Hassan Saleh Abdullatif, Albahloul Mohamed Albahloul Salem, Khedr Abdalla Mohamed, El-Kholey Sohier Mahmoud
Applied Medical Chemistry Department, Medical Research Institute, Alexandria University, Alexandria, Egypt.
Medical Biophysics Department, Medical Research Institute, Alexandria University, Alexandria, Egypt.
BMC Cancer. 2025 May 19;25(1):896. doi: 10.1186/s12885-025-14285-8.
Micro-photodynamic therapy (MWPDT) combines photo-dynamic (PDT) and microwave-dynamic (MWDT) therapies with sensitizers, offers new avenues for cancer treatment. Despite the fact that novel sensitizers for MWPDT have been successfully synthesized, only a few are being employed effectively. The low tumor-targeting specificity, inability to transport sensitizer's deeper intratumorally, and deteriorating tumor microenvironment all restrict their anti-tumor efficacy. The current work was done aiming at microwave assisted drug delivery of titanium dioxide / rose Bengal conjugated chitosan nanoparticles (TiO/RB@CSNP) for micro- photo-dynamic skin cancer (SKCA) treatment in vitro and in vivo as activated cancer treatment up-to-date modality.
The study was conducted in vitro on human SKCA cells (A-375) and the study protocol application groups in vivo on Swiss albino mice treated with 7,12-dimethylbenz[a]anthracene (DMBA)/croton oil only and were not received any treatment for inducing SKCA, and only after SKCA induction the study treatment protocol began, treatment was daily with TiO/RB@CSNP as MWPDT sensitizer with or without exposure to laser (IRL) or microwave (MW) or a combination of them for 3 min for two weeks.
Revealed that CSNP can be employed as effective TiO/RB delivery system that directly targets SKCA cells. Additionally TiO/RB@CSNP is a promising MWPS for and when combined with MWPDT can be very effective in treatment of SKCA-A-375 in vitro (cell viability decreased in a dose-dependent basis, the cell cycle progression in G0/G1 was slowed down, and cell death was induced as evidenced by an increase in the population of Pre-G cells, an increase in early and late apoptosis and necrosis, and an increase in autophagic cell death) and DMBA/croton oil SKCA-induce mice in vivo (induced antiproliferative genes (caspase 3,9, p53, Bax, TNFalpha), suppressed antiapoptotic and antiangiogenic genes (Bcl2,VEGF respectively) effectively reducing the tumors growth and leading to cancer cell death as well as decreased oxidative stress (MDA), and ameliorated enzymatic and non-enzymatic antioxidants (SOD, GR, GPx, GST, CAT, GSH, TAC) as well as renal (urea, creatinine) and hepatic (ALT, AST) functions. This process could be attributed to MWPDT; microwave and/or photo-chemical TiO/RB activation mechanism and antioxidant potential of non activated TiO/RB as well.
The results indicate that TiO/RB@CSNP has great promise as an innovative, effective delivery system for selective localized treatment of skin cancer that is activated by MWPDT.
微光动力疗法(MWPDT)将光动力(PDT)和微波动力(MWDT)疗法与敏化剂相结合,为癌症治疗提供了新途径。尽管已成功合成了用于MWPDT的新型敏化剂,但只有少数几种得到有效应用。低肿瘤靶向特异性、无法将敏化剂更深入地转运至肿瘤内部以及肿瘤微环境恶化均限制了它们的抗肿瘤疗效。当前的研究旨在通过微波辅助递送二氧化钛/孟加拉玫瑰红共轭壳聚糖纳米颗粒(TiO/RB@CSNP),用于体外和体内微光动力皮肤癌(SKCA)治疗,作为一种最新的激活癌症治疗方式。
该研究在体外对人SKCA细胞(A-375)进行,体内研究方案应用组则是对仅用7,12-二甲基苯并[a]蒽(DMBA)/巴豆油处理且未接受任何诱导SKCA治疗的瑞士白化小鼠进行,仅在诱导SKCA后开始研究治疗方案,每天用TiO/RB@CSNP作为MWPDT敏化剂进行治疗,同时或不暴露于激光(IRL)或微波(MW)或它们的组合下3分钟,持续两周。
表明CSNP可作为有效的TiO/RB递送系统,直接靶向SKCA细胞。此外,TiO/RB@CSNP是一种有前景的MWPS,当与MWPDT联合使用时,在体外对SKCA-A-375的治疗非常有效(细胞活力呈剂量依赖性下降,G0/G1期细胞周期进程减慢,Pre-G细胞群体增加、早期和晚期凋亡及坏死增加以及自噬性细胞死亡增加证明诱导了细胞死亡),在体内对DMBA/巴豆油诱导的SKCA小鼠也有效(诱导抗增殖基因(半胱天冬酶3、9、p53、Bax、TNFα),抑制抗凋亡和抗血管生成基因(分别为Bcl2、VEGF),有效减少肿瘤生长并导致癌细胞死亡,同时降低氧化应激(MDA),改善酶促和非酶促抗氧化剂(超氧化物歧化酶、谷胱甘肽还原酶、谷胱甘肽过氧化物酶、谷胱甘肽S-转移酶、过氧化氢酶、谷胱甘肽、总抗氧化能力)以及肾脏(尿素、肌酐)和肝脏(谷丙转氨酶、谷草转氨酶)功能。这一过程可归因于MWPDT;微波和/或光化学TiO/RB激活机制以及未激活的TiO/RB的抗氧化潜力。
结果表明,TiO/RB@CSNP作为一种通过MWPDT激活的用于皮肤癌选择性局部治疗的创新、有效递送系统具有很大潜力。